Loading
A phase 2 trial of Mosunetuzumab, Tocilizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Genentech, Inc., active and no longer recruiting.
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies is a phase 2 interventional study registered as NCT05207670 by Genentech, Inc., with 320 participants enrolled, started 2022-02-01 and due to reach its primary completion in 2027-07-31. Interventions recorded: Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tocilizumab, Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Tocilizumab, Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Tocilizumab, Roche / Genentech, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Shares Tocilizumab, Roche / Genentech, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Shares Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Roche / Genentech, T-cell engagers (bispecific), Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Tocilizumab, Roche / Genentech.
Shares Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/